Latest From Indivior PLC
Indivior is working on receiving ex-US approvals for its opioid abuse treatment products and building its cash reserves but faces future uncertainty over US generic competition and a US Department of Justice legal action.
Agency's decision that Indivior’s Sublocade blocked Braeburn’s long-acting buprenorphine formulation Brixadi lacked ‘substantive guideposts’ in how innovation is defined for purposes of deciding scope of three-year exclusivity, US judge says.
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- Reckitt Benckiser Pharmaceuticals Inc.
- Western Europe
- Parent & Subsidiaries
- Indivior PLC
- Senior Management
Shaun Thaxter, CEO
Mark Crossley, CFO
Ponni Subbiah, MD, CMO
Christian Heidbreder, PhD, CSO
Richard Simkin, Chief Commercial Officer
- Contact Info
Phone: (0)1753 217800
215 Bath Rd.
Slough, SL1 4AA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.